Belite Bio Inc ADR (BLTE) - Total Liabilities
Based on the latest financial reports, Belite Bio Inc ADR (BLTE) has total liabilities worth $15.48 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Belite Bio Inc ADR's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Belite Bio Inc ADR - Total Liabilities Trend (2020–2025)
This chart illustrates how Belite Bio Inc ADR's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Belite Bio Inc ADR.
Belite Bio Inc ADR Competitors by Total Liabilities
The table below lists competitors of Belite Bio Inc ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Coromandel International Limited
NSE:COROMANDEL
|
India | Rs-131.33 Billion |
|
Rayonier Inc
NYSE:RYN
|
USA | $1.20 Billion |
|
Clal Insurance Enterprises Holdings Ltd
TA:CLIS
|
Israel | ILA175.99 Billion |
|
Covivio SA
PA:COV
|
France | €12.69 Billion |
|
GPT Group
AU:GPT
|
Australia | AU$6.30 Billion |
|
Ford Otomotiv Sanayi AS
IS:FROTO
|
Turkey | TL276.72 Billion |
|
thyssenkrupp AG
F:TKA1
|
Germany | €17.74 Billion |
|
United Integrated Services Co Ltd
TW:2404
|
Taiwan | NT$53.22 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Belite Bio Inc ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Belite Bio Inc ADR's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 33.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Belite Bio Inc ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Belite Bio Inc ADR (2020–2025)
The table below shows the annual total liabilities of Belite Bio Inc ADR from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.07 Million | +59.56% |
| 2024-12-31 | $6.31 Million | +49.87% |
| 2023-12-31 | $4.21 Million | +51.91% |
| 2022-12-31 | $2.77 Million | -91.71% |
| 2021-12-31 | $33.44 Million | +2.02% |
| 2020-12-31 | $32.78 Million | -- |
About Belite Bio Inc ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and … Read more